AbsTrACT background the list of Mendelian disorders of the epigenetic machinery has expanded rapidly during the last 5 years. A few missense variants in the chromatin remodeler CHD1 have been found in several large-scale sequencing efforts focused on uncovering the genetic aetiology of autism.
AbsTrACT background the list of Mendelian disorders of the epigenetic machinery has expanded rapidly during the last 5 years. A few missense variants in the chromatin remodeler CHD1 have been found in several large-scale sequencing efforts focused on uncovering the genetic aetiology of autism. Objectives to explore whether variants in CHD1 are associated with a human phenotype. Methods We used GeneMatcher to identify other physicians caring for patients with variants in CHD1. We also explored the epigenetic consequences of one of these variants in cultured fibroblasts. results here we describe six CHD1 heterozygous missense variants in a cohort of patients with autism, speech apraxia, developmental delay and facial dysmorphic features. Importantly, three of these variants occurred de novo. We also report on a subject with a de novo deletion covering a large fraction of the CHD1 gene without any obvious neurological phenotype. Finally, we demonstrate increased levels of the closed chromatin modification h3K27me3 in fibroblasts from a subject carrying a de novo variant in CHD1. Conclusions our results suggest that variants in CHD1 can lead to diverse phenotypic outcomes; however, the neurodevelopmental phenotype appears to be limited to patients with missense variants, which is compatible with a dominant negative mechanism of disease.
There has been rapid discovery of the genetic aetiologies of intellectual disability with the advent of single nucleotide polymorphism microarray and clinical trio-based exome sequencing in recent years.
1 Many of the newly discovered genetic variants are found in components of the epigenetic machinery. 2 3 Patients with these disorders often display variable intellectual disability, growth dysregulation and facial/limb dysmorphic features 3 ; the variability may be caused by individual variants but also by interaction with genetic or epigenetic variation at target genes. 3 4 There are approximately 300 known epigenetic factors to date and currently about 50 (17%) have been associated with discernible phenotypes. 3 5-9 The epigenetic machinery consists of readers, writers and erasers of epigenetic modifications, as well as remodelers of chromatin, of which the latter three classes are enzymes.
Enzymes are a class of proteins which is usually tolerant to the loss of a single allele; however, a deleterious pathogenic variant on a single allele of components of the epigenetic machinery appears to be sufficient to cause a clinical phenotype in a large majority of these diseases. This suggests that dosage may be critically important for enzymatic components of the epigenetic machinery. 3 A number of well-known disease entities have been found to be associated with dysfunctional chromatin remodelers, including Coffin-Siris syndrome (MIM:135900), 10 CHARGE syndrome (Coloboma, Heart anomaly, choanal Atresia, Retardation, Genital and Ear anomalies; MIM: 214800) 11 and ATR-X syndrome (Alpha Thalassemia/ mental Retardation syndrome, X-Linked; MIM: 301040). 12 Among the CHD (chromodomain, helicase, DNA binding) family of ATP-dependent chromatin remodelers, Mendelian disease phenotypes have so far been linked to four genes, CHD2, CHD4, CHD7 and CHD8, and common features are intellectual disability, autism and abnormal head size (see online supplementary table S1). For three of these (CHD2, CHD7 and CHD8), the predominant variant type appears to be loss of function. In contrast, only missense variants have been found in CHD4. Sequencing of tumours has also revealed variants in the CHD gene family in cancer; variants in CHD5 have been found in neuroblastoma, 13 and variants in the other CHD genes (1-4 and 7-9) have been found in tumours of the gut (gastric and colorectal cancers). 14 15 CHD1 is an ATP-dependent chromatin remodeler, 16 encoded on the long arm of chromosome 5.
17 CHD1 has two chromodomains 18 19 that bind to H3K4me3/H3K4me2. 19 CHD1 regulates the opening of chromatin and contributes to the pluripotency of embryonic stem cells. 20 It may play a role in transcript elongation 21 and help to deposit the H3.3 histone variant.
22 CHD1 is expressed in many tissues including in the brain, where the highest level of expression is found in the cerebellum and basal ganglia (see online supplementary figure S1).
In our Epigenetics and Chromatin Clinic (https:// igm. jhmi. edu/ ecc-clinic), we saw two unrelated individuals with missense variants in CHD1 (subjects 1 and 2). We submitted an entry into GeneMatcher, 23 and made contact with several clinical groups and New disease loci the genetic testing company GeneDx. This resulted in six individuals described here with single nucleotide variants, all of whom underwent whole exome sequencing at GeneDx, which has performed more than 50 000 clinical whole exome sequencing tests to date (January 2017).
In addition to the three new individuals that we identified with de novo heterozygous missense variants in CHD1 (figure 1A, subjects 1, 4, 5), we also found that de novo missense (L1016V, R1203Q) [24] [25] [26] and nonsense (L1517fs*) 26 27 variants in CHD1 were previously described in three individuals with autism (figure 1A, grey) identified in large surveys of autistic individuals. [24] [25] [26] [27] However, the available phenotypic information is limited, so it is unknown whether these subjects show phenotypic overlap beyond autism.
Likely disease-causing variants were also identified in three other individuals, though it could not be determined whether the change was de novo or not. These included two affected sisters (subjects 2 and 3) conceived by separate in vitro fertilisation cycles using eggs from a single, presumably healthy egg donor for which CHD1 sequencing is unavailable, and a female (subject 6) for whom parental samples are not available as the child is adopted ( figure 1A ). Phenotypic data of these individuals are described in table 1, but parental biological samples are unavailable.
Four of our subjects with CHD1 mutations carried a diagnosis of speech apraxia. Three of these subjects also received a diagnosis of autism, although one (subject 1) no longer carries this diagnosis. Speech apraxia is a relatively rare (1-2/1000 children) diagnosis in the general population. 28 However, a recent study suggests that speech apraxia is seen in a large portion of children with autism. 29 Furthermore, both apraxia and autistic phenotypes have in recent years been linked more heavily to the cerebellum [30] [31] [32] and the CHD1 chromatin factor is highly expressed in the cerebellum (see online supplementary figure S1). All five subjects for which phenotypic information is provided had developmental delay and hypotonia; all are female and some had epileptiform abnormalities on an EEG (table 1) . Although autism is in general more common in boys, the six subjects we observe with CHD1 mutations are all girls. Attention should be given in future studies to the sex of individuals harbouring CHD1 mutations and if a female skew is observed in larger cohorts, consideration should be given to the mechanism of male intolerance of CHD1 mutations. A subset of subjects had dysmorphic features including a pointed chin, frontal bossing and arched eyebrows (figure 1B) (and Supplementary figure S2) .
Although we include information about the de novo variant found in subject 5 (D857G), this individual also carried compound heterozygous variants in the WDR62 gene which were thought to be disease causing. Variants in WDR62 are the cause of microcephaly 2, primary, autosomal recessive, with or without cortical malformation (MIM: 604317). Therefore, no phenotypic information about this subject (subject 5) is included, as her notable cortical malformation likely accounted for her global developmental delay. Additional phenotypic contributions of the de novo D857G variant in the CHD1 gene in this subject could not be discerned at 2 years of age.
All subjects identified in this study carried missense variants in CHD1. Given the absense of loss of function alleles, we hypothesise that there is a dominant negative mechanism of disease in the case of CHD1 mutations and their association with neurodevelopmental disability. Five of the six new variants described here involved a loss of an arginine and several are located in Figure 1 Missense variants in the chromatin remodeler CHD1 result in a distinct neurological syndrome with dysmorphic features. (A) We have identified five unrelated subjects with missense variants at highly conserved locations within the coding region of the CHD1 gene. three of these variants are confirmed to be de novo. three other de novo variants previously described in large cohorts of subjects with autism [24] [25] [26] [27] are noted in grey. two of these variants occur at heavily conserved sites (1016, 1203) and the other (1517) leads to a frameshift at the C-terminal end of the protein. ChCt, which stands for ChD1 helical C-terminal, is an alpha-helical domain of unknown function. 43 Domain boundaries are based on Chd1 structures. structurally important regions. This recurrent loss of arginine may offer a potential clue towards the mechanism of the pathogenicity, as even when we take into account the arginine richness of this protein (7% of all amino acids), there is still a statistically significant enrichment of these missense changes involving arginine over what could be expected by chance (p=9.3×10 −5 ). One of these changes, Arg618Gln, substitutes a glutamine for a conserved arginine residue that is adjacent to the Walker B helicase motif which is central for the hydrolysis of ATP. Although the precise function of this arginine is not presently known, its positioning suggests that it may help couple DNA binding to ATP hydrolysis ( figure 1C ). All of these variants occurred at highly conserved amino acids ( figure 1A ) and most were deemed pathogenic by both PolyPhen 33 (table 1) and SIFT (data not shown). 34 No variants have been described at amino acid position 460 and 618 in the ExAC database 35 of healthy individuals. However, there was a single description of a variant changing the arginine at amino acid position 141 to a serine (frequency of <1/10 −5 ) but no variants have been described that change arginine at 141 to a glycine in CHD1. The change to glycine at 141 disrupts the conserved basic character at this residue, which may disrupt the protein structure or function. Similarly, there are 23 occurrences of a substitution from arginine to tryptophan at position 1708 (less than 0.03% of the ExAC database), but no observed changes of arginine to glutamine at this position in CHD1. Constraint data from the ExAC database also revealed that missense variants are generally poorly tolerated in this gene (z=3.26, figure 1D ), as are loss of function variants (pLI=1). In three of the unrelated subjects, the variants were found to be de novo in the probands, further supporting the potential significance of these variants for the phenotype of our subjects. Additionally, CHD1 has been shown to bind to numerous key factors involved in transcriptional regulation, such as FACT, SPT4-5, RTF1, and components of large complexes such as Mediator and the spliceosome. [36] [37] [38] It is possible that an inactivating mutation, such as is seen for many missense mutations, in the CHD1 protein could titrate out important factors or reduce the occupancy of active CHD1 at targeted sites, which could offer an explanation for a dominant negative mechanism of disease.
Moreover, data from DECIPHER (https:// decipher. sanger. ac. uk), as well as the high predicted intolerance of CHD1 to loss of function variants (pLI=1 in ExAC), lend further evidence to the contribution of CHD1 to disease. For instance, seven deletions overlapping the CHD1 gene are available from DECIPHER 39 ; six of these ranged from 5.64 to 12.10 Mb and involved a large number of genes. The smallest of these copy number variants was a 2.95 Mb deletion with a loss of six genes in a patient with hypotonia, constipation and language delay (see online Subject 2 has been treated with a ketogenic diet and carries another variant of unknown significance from her unaffected father (DEPDC5, c1355 C>T, pA452V; reference transcript: NM_001242896.1). Subject 4 was seen again at 16 months and had less delay at that time (5-10 words, waves bye) although was still receiving supportive services (occupational therapy). Her measurements at that point included a height of 77.5 cm (33rd %ile), a weight of 10 kg (56th %ile) and a head circumference of 44.5 cm (16th %ile). One of the parents of subject 6 also has intellectual disability but has not been available for genetic testing. Subject 1 had frequent episodes of fevers and inflammation, with fever ranging up to 104° Farenheit with swelling of face and bags under eyes. Immune testing showed incomplete vaccination to pneumococcus but responded to extra booster, an elevated Immunoglobulin E, and reduced natural killer cell function. Subjects 2 and 3 both have immune problems which include Immunoglobulin A deficiency and hypogammaglobulinaemia. Other features observed in subject 1 include constipation, flexibility (family history of Ehlers-Danlos s yndrome) and high pain threshold. Although subject 1 never had growth retardation, she is small compared with other family members and had poor growth after being 8 lbs at birth. Subject 1 inherited another variant of unknown significance from her unaffected mother (CACNA1H, c.5608 G>A, p.A1870T). %ile, percentile; Ben, benign;PoD, possibly damaging; PrD, probably damaging. Reference transcript for CHD1 is NM_001270.2.
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supplementary table S2). However, in addition to CHD1, there were other candidate genes within this deletion that could potentially explain the observed phenotype (see online supplementary table S2). Interestingly, there is also a recent description of an individual with isolated talipes equinovarus and a de novo deletion of the entire sequence of RGMB and the final nine exons of CHD1 (Hg18, Chr5:97916544-98250268). 40 However, we now confirm that this previously described individual, a 9-year-old boy, has no obvious neurodevelopmental phenotype at this time and that he is generally healthy other than the clubfoot and asthma. This evidence suggests that deletions of CHD1 may not cause a consistent neurological phenotype, but missense changes in CHD1 may, through a dominant negative mechanism. Alternatively, changes in CHD1 (both deletions and missense changes) could lead to a predisposition towards disease similar to what has been described for CHD8, but may not be fully penetrant. In addition, Chd1 has been found to be essential for the high transcriptional output needed for rapid growth of the mouse epiblast 41 and it has also been found to play a role in later murine development. 42 Despite this, mice with loss of a single CHD1 allele (Chd1 +/-) are healthy, fertile and phenotypically normal. 41 Collectively, these observations highlight that further research is needed to elucidate the consequences of loss of function mutations in CHD1. However, we think that, together, these data are compatible with the hypothesis that the neurodevelopmental phenotype is associated with a dominant negative disease mechanism of missense mutations in CHD1.
Since prior studies demonstrate that dysregulation of CHD1 leads to global changes in chromatin, 20 we explored the functional consequences of one of these variants in fibroblasts from subject 1. In these fibroblasts, which carry a heterozygous de novo variant (Arg618Gln), we observed a global increase of a closed chromatin modification (H3K27me3) compared with fibroblasts from control individuals (figure 2). These data support the notion that missense changes such as Arg618Gln have functional effects on CHD1 function.
In summary, our data show that missense variants in the chromatin remodeler CHD1 are associated with a novel neurodevelopmental disorder with intellectual disability, autism, seizures, speech apraxia and dysmorphic features.
Figure 2 patient fibroblasts demonstrate increased amounts of a closed chromatin modification (h3K27me3) compared with fibroblasts from control subjects. Since ChD1 is thought to play an active role in the process of opening chromatin, we examined the amount of h3K27me3 in fibroblasts from one of our subjects (subject 1) and fibroblasts from two control individuals. Briefly, samples were cultured in triplicate and stained with antibodies against h3K27me3 (green) and DApI (4',6-Diamidino-2-phenylindole dihydrochloride), a nucleic acid stain (blue). Intensity level of h3K27me3 in each nucleus was quantified using ImageJ. (A) representative images of immunofluorescence staining from subject 1 and two controls. (B) Quantification of h3K27me3 intensity, normalised to the average control intensity. Grey points represent h3K27me3 intensity in each nucleus and black bars represent the mean intensity of all nuclei measured. Controls were age and sex matched (karyotypes: 46,XX and 46,XX,del(22)(q11.2q11.2)). *p<0.05, ***p<0.0005, one-way analysis of variance with post hoc tukey's hSD (honest Significant Difference) analysis.
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